Dirk Arnold

3 weeks ago | ajmc.com | Pearl Steinzor |Dirk Arnold |Vincent J. Picozzi |Danny Rischin

Oncology professionals reflect on the unique value of attending the American Society of Clinical Oncology (ASCO) annual meeting—from discovering new clinical trial results to reconnecting with peers from around the world. With major practice-changing research and global thought leadership in one place, ASCO continues to be a can't-miss event for the cancer care community.

3 weeks ago | ajmc.com | Pearl Steinzor |Dirk Arnold

The OriAMI-2 study (NCT06662786) was designed to compare amivantamab, a novel bispecific antibody targeting EGFR and MET receptors, with standard chemotherapy to potentially improve treatment outcomes in patients with metastatic colorectal cancer (mCRC), says Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre. The study was presented at the American Society of Clinical Oncology (ASCO) meeting. This transcript was lightly edited; captions were auto-generated.